OM1 expands real-world data to help advance Parkinson’s research

OM1 expands real-world data to help advance Parkinson’s research

OM1 has expanded a real-world dataset of people with neurological conditions, including Parkinson’s disease, adding health records and clinical notes for 500,000 more people. “Expanding our neurology network to more than 3 million patients represents a pivotal milestone in enabling better outcomes for neurology patients,” Carl Marci, MD,…

MJFF, Seal Rock collaboration eyes LRRK2 gene-targeting therapies

Seal Rock Therapeutics has joined a Michael J. Fox Foundation (MJFF) initiative to develop therapies targeted at the LRRK2 gene for the treatment of Parkinson’s disease. The program, LRRK2 Investigative Therapeutics Exchange (LITE), brings together academic and industry collaborators to support preclinical and clinical development aimed…

Parkinson’s fall prevention program gets high marks from most users

Most people with Parkinson’s disease who’d experienced recurring falls found a personalized, home-based fall prevention program in Australia helpful for improving their safety and confidence. That’s according to a new assessment of the six-month program, dubbed Integrate, which was shown to reduce fall rates by nearly half among participants…